Page 1 | Search Results | The Hematologist | American Society of Hematology

Skip Nav Destination

1-19 of 19

Sort by

Sort Order Select

Articles

Eltrombopag in Frontline Therapy for Severe Aplastic Anemia: A RACE Against Time

Nirija Ranjit Anderson, MBBS (HONS I), BPHARM, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2022) 19 (3)

https://doi.org/10.1182/hem.V19.3.2022312

Published: 2022

Articles

Oral Maintenance Therapy to Improve Survival in Older Patients With AML

Nathan Klose, MBBS, FRACP, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2022) 19 (1)

https://doi.org/10.1182/hem.V19.1.202213

Published: 2022

Articles

Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers

Michael J. Lane, BSc, MBBS, FRACP, FRCPA, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2021) 18 (6)

https://doi.org/10.1182/hem.V18.6.202163

Published: 2021

Articles

Bypass, Escape, or Mutate: The Resistant Clones in Midostaurin-treated FLT3 -ITD AML

Joshua Sheehy, MD, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2021) 18 (5)

https://doi.org/10.1182/hem.V18.5.202153

Published: 2021

Articles

Targeting TP53 Mutants in Myeloid Neoplasms: Are We There Yet?

Jane Royle, MBBS, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2021) 18 (4)

https://doi.org/10.1182/hem.V18.4.202141

Published: 2021

Articles

Just As Good but Better Tolerated: Posaconazole As First-line Therapy for Invasive Aspergillosis

Adam G. Stewart, BBiomedSci, MBBS (Hons), MPHTM, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2021) 18 (3)

Published: 2021

Articles

Rallying Macrophages in the Fight Against MDS and AML

Andrew A. Guirguis, MBBS, PhD, FRACP, FRCPA, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2021) 18 (2)

Published: 2021

Articles

Not All TP53 Mutations Are Equal

Yatika Jivan, MBBS, FRACP, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2020) 18 (1)

Published: 2020

Articles

A New Path to Remission for Older Patients With AML

Steven Lane, MBBS, PhD, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA

The Hematologist (2020) 17 (6)

Published: 2020

Articles

Does the Immune System Matter in Treatment for AML?

Jacqueline Taylor, MBBS (Hons), Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2020) 17 (5)

Published: 2020

Articles

Taking the Brakes Off Programmed Cell Death: Will It Work for AML in Older Patients?

Claudia Bruedigam, PhD, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2020) 17 (4)

https://doi.org/10.1182/hem.V17.4.12884901938

Published: 2020

Articles

Gut Microbiome Diversity Influences Transplant Risk

Steven Lane, MBBS, PhD, FRACP, FRCPA, Julian Grabek, MBBS, FRACP, FRCPA

The Hematologist (2020) 17 (3)

https://doi.org/10.1182/hem.V17.3.10374

Published: 2020

Articles

Menin Inhibitors: A New Hope in MLL-Rearranged Leukemia?

Steven Lane, MBBS, PhD, FRACP, FRCPA, Renee Squires, MBBS

The Hematologist (2020) 17 (2)

https://doi.org/10.1182/hem.V17.2.10240

Published: 2020

Articles

Mapping Functional Susceptibilities in AML

Steven Lane, MBBS, PhD, FRACP, FRCPA, Andrea Henden, MBBS, PhD, FRACP, FRCPA

The Hematologist (2020) 17 (1)

https://doi.org/10.1182/hem.V17.1.10162

Published: 2020

Articles

Interferon in Low-risk Polycythemia Vera: Does Better Tolerability Allow for Earlier Intervention?

Steven Lane, MBBS, PhD, FRACP, FRCPA, Florian H. Heidel, MD

The Hematologist (2019) 16 (6)

https://doi.org/10.1182/hem.V16.6.9940

Published: 2019

Articles

TARGETing Genetic Drivers of MPN at Single Cell Resolution

Jasmin Straube, BSc, MSc, PhD, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2019) 16 (5)

https://doi.org/10.1182/hem.V16.5.9801

Published: 2019

Articles

Piecing Together the Bone Marrow Niche

Victoria Y. Ling, MBBS, FRACP, FRCPA, Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2019) 16 (4)

https://doi.org/10.1182/hem.V16.4.9639

Published: 2019

Articles

Unraveling the Loops of Drug Resistance in ALL

Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2019) 16 (3)

https://doi.org/10.1182/hem.V16.3.9525

Published: 2019

Articles

Beating AML: Know Your Enemy

Steven Lane, MBBS, PhD, FRACP, FRCPA

The Hematologist (2019) 16 (2)

https://doi.org/10.1182/hem.V16.2.9454

Published: 2019

NARROW

Eltrombopag in Frontline Therapy for Severe Aplastic Anemia: A RACE Against Time

Oral Maintenance Therapy to Improve Survival in Older Patients With AML

Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers

Bypass, Escape, or Mutate: The Resistant Clones in Midostaurin-treated FLT3 -ITD AML

Targeting TP53 Mutants in Myeloid Neoplasms: Are We There Yet?

Just As Good but Better Tolerated: Posaconazole As First-line Therapy for Invasive Aspergillosis

Rallying Macrophages in the Fight Against MDS and AML

Not All TP53 Mutations Are Equal

A New Path to Remission for Older Patients With AML

Does the Immune System Matter in Treatment for AML?

Taking the Brakes Off Programmed Cell Death: Will It Work for AML in Older Patients?

Gut Microbiome Diversity Influences Transplant Risk

Menin Inhibitors: A New Hope in MLL-Rearranged Leukemia?

Mapping Functional Susceptibilities in AML

Interferon in Low-risk Polycythemia Vera: Does Better Tolerability Allow for Earlier Intervention?

TARGETing Genetic Drivers of MPN at Single Cell Resolution

Piecing Together the Bone Marrow Niche

Unraveling the Loops of Drug Resistance in ALL

Beating AML: Know Your Enemy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only